CRITICAL EVALUATION OF MODIFIED-RELEASE FORMULATION CONTAINING Silybum Marianum EXTRACT FOR ORAL APPLICATION

DÁVID SINKA 1#, ALEXANDRA HAGYMÁSI 1, PÁLMA FEHÉR 1, ZOLTÁN UJHELYI 1, MIKLÓS VECSENYÉS 1, FERENC FENYVESI 1, JUDIT VÁRADI 1, GÁBOR VASVÁRT 1, TÜNDE JURCA 2, SEBASTIAN NEMETH 2#, DANIELA ELENA POPA 3#, ILDIKÓ BÁCSKAY 1#

1Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Debrecen, Hungary
2Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, Oradea, Romania
3Department of Drug Control, Faculty of Pharmacy, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania

*corresponding author: bacskay.ildiko@pharm.unideb.hu
#Authors with equal contribution.

Abstract

Silymarin is the extract of active ingredients of the plant Silybum marianum. It is used in medicine for curing or preventing liver and gall diseases for thousands of years. Silymarin has a low solubility and permeability, belongs to BCS class IV. Its current pharmacotherapy means conventional dosage forms such as capsules, but it results in low bioavailability. Our main goals through the research were to formulate matrix tablets with silymarin as active ingredient. We used different carbopols as matrix-forming polymers. The complexation of silymarin with different β-cyclodextrins was intended to increase the solubility of the active ingredient. By achieving sustained release, our aim was to offer a better alternative than the conventional unsuccessful oral therapy. Comparing the results of our research, we could select the carbopol-cyclodextrin combination with the optimal drug release from the twenty different compounds. With these compositions, more than 85% of the silymarin was dissolved. The cytocompatibility of our product was proven, and the technology provided much better bioavailability than the conventional silymarin therapy.

Rezumat

Silimarina reprezintă extractul de ingredient active din planta Silybum marianum, care de mii de ani se folosește în medicina tradițională pentru prevenirea și vindecarea bolilor hepatice și biliare. Silimarina are o solubilitate și permeabilitate scăzută, aparține clasei IV BCS. Farmacoterapia actuală constă în forme de dozare convențională, cum ar fi capsule, dar care prețează o biodisponibilitate scăzută. Cercetările noastre au avut ca obiectiv principal formularea de comprimate matrix cu silimarina ca ingredient activ. Am folosit diferiți carbopoli ca polimeri care formează matrix. Complexarea silimarinei cu diferite β-ciclodextrine a avut rolul de a crește solubilitatea ingredientului activ. Prin realizarea eliberării susținute, scopul nostru a fost să oferim o alternativă mai bună decât terapia convențională orală. Comparând rezultatele cercetării noastre, putem scoate în evidență combinația carbopol-ciclodextrină cu eliberarea optimă a medicamentului din cele douăzeci de compuși diferenți studiați. Cu aceste compoziții, mai mult de 85% din silimarina a fost dizolvată. Citocompatibilitatea produsului nostru a fost dovedită, tehnologia oferind o biodisponibilitate mult mai bună decât terapia convențională cu silimarina.

Keywords: modified-release, Silybum marianum, cyclodextrin, HPBCD, Caco-2 cells

Introduction

Silymarin is the active pharmaceutical ingredient (API) of the plant Silybum marianum (milk thistle). It is a flavonolignan complex, having the attention of scientists since the beginning of the flavonolignan researches [4]. Its components were separated by high performance liquid chromatography/tandem mass spectrometry. The main bioactive ingredients included silychristins A and B, silydianin, silybin A and B, isosilybin A and B, and three further components were partly separated, presumably two silybin stereoisomers and one isosilybin stereoisomer [26].

The aforementioned flavonoids possess several effects like antioxidant, anticancer and cell regenerating effect [7, 31-34]. Because of these properties, milk thistle has been used as an herbal medicine through centuries. Its usage covered treating liver and gallbladder diseases, and as an antidepressant, because of the historical theory that melancholy caused by “bad bile” or liver related problems [41]. Evidence based medicine started to investigate milk thistle in the second half of the 20th century. A wide range of effects were explored by both topical and oral use. Silymarin has anti-inflammatory and anti-erythmic effects [40], as well as potential in skin protection [8]. The antioxidant
properties of silymarin inhibit oxidative stress and prevent skin cancer [18, 19]. Topical silymarin can influence enzymatic (superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase, glutathione-S-transferase) and non-enzymatic physiological defence systems of the skin, therefore decrease ROS (reactive oxygen species) production and, which is the main cause of oxidative stress, inflammation and skin cancer [5]. However, silymarin is mainly used orally, as an agent being hepatoprotective, usable in prevention and treatment of cancer, gastrointestinal problems, cardiopulmonary problems, nephropathy, neuropathy, and being antidote of different toxins [13, 16, 25, 29]. As studies have shown, the effects of orally applied silymarin are including the stimulation of ribonucleic acid (RNA) polymerase I, ribosomal RNA synthesis and proteo-synthesis [45], free radical scavenging activity and ability to increase cellular glutathione level resulting in activity against lipid peroxidation, capacity to regulate nuclear expression, inhibition of myofibroblast formation from hepatocytes, and the ability to regulate membrane permeability and to increase membrane stability in the presence of xenobiotic damage [7]. Many articles were published about the background of the Silybum marianum effects, applications etc. Silybum marianum have been in focus of complex investigations, because of the small number of effective hepatoprotective drugs on the market. One of the oldest formulation with silymarin as API is from the 1st century, involving juice extract and honey [41]. Nowadays, oral administration of silymarin usually means conventional tablets or mainly capsules containing powdered milk thistle extracts. There are much less oil, syrup or suspension products on the market [53]. However, silymarin is poorly soluble in water, which leads to limited bioavailability and limited effective dosage forms. Improved preparations are needed to exploit the benefits fully [6]. Studies described 20 - 50 percent of the orally administered silymarin absorbed from the gastrointestinal tract, or even as low as 0.73% bioavailability in rat plasma [12, 49]. Several researches targeted silymarin in the past years to increase its solubility and bioavailability. New silybin derivatives, liposomes and targeted liposomes, phytosomes, microemulsion and Self Micro-Emulsifying Drug Delivery Systems (SMEDDS), solid dispersion systems, different carriers such as lipid nanoparticles, polymeric micelles, or fulvic acid, floating tablets and micronization are all possibilities to bypass the problem of silymarin [11, 24, 35, 43, 45, 50]. Complexation with liposomal structures, phospholipids or β-cyclodextrins is a way to increase solubility of drugs in the Class IV of the BCS (Biopharmaceutical Classification System). β-cyclodextrins are among the widely used host molecules for inclusion complexes [2, 10] studied the formulation of silymarin - β-cyclo-dextrin inclusion complexes with different methods. Their results suggest a 1:1 complex formation in the case of physical mixture. Stability constant was 722 K⁻¹.

<table>
<thead>
<tr>
<th>Possibility</th>
<th>Result</th>
<th>Disadvantage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemical modification</td>
<td></td>
<td></td>
</tr>
<tr>
<td>silybin derivatives</td>
<td>superior antioxidant properties possible</td>
<td>low water solubility</td>
</tr>
<tr>
<td>prodrug</td>
<td>even 30 times more soluble</td>
<td>lower hepatoprotective potency</td>
</tr>
<tr>
<td>silybin glycoside</td>
<td>improved hepatic cell uptake and solubility</td>
<td>not the total extract</td>
</tr>
<tr>
<td>Complexation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>phospholipids</td>
<td>increased absorption, lower therapeutic</td>
<td>not the total extract</td>
</tr>
<tr>
<td>dose, better stability profile</td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-cyclodextrins</td>
<td>6-times higher bioavailability in vivo</td>
<td>cell toxicity considerations</td>
</tr>
<tr>
<td>Conventional dosage forms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>floating tablets</td>
<td>prolonged gastric time</td>
<td>dissolution in the stomach and not in the small intestines</td>
</tr>
<tr>
<td>solid dispersions</td>
<td>higher solubility</td>
<td>instability considerations</td>
</tr>
<tr>
<td>micronization</td>
<td>enhanced dissolution rate</td>
<td>high energy requirements</td>
</tr>
<tr>
<td>Novel dosage forms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>liposomes</td>
<td>enhanced gastrointestinal absorption</td>
<td>difficult in large scale manufacturing</td>
</tr>
<tr>
<td>nanoparticles</td>
<td>enhanced dissolution</td>
<td>toxicity considerations</td>
</tr>
<tr>
<td>microspheres</td>
<td>higher dissolution percentage</td>
<td>released pharmacon still under 60% in 36 hours</td>
</tr>
<tr>
<td>SMEDDS</td>
<td>more than 3-times higher bioavailability</td>
<td>high content of surfactants can lead to irritation</td>
</tr>
<tr>
<td>sustained release</td>
<td>controlled release of components</td>
<td>solubility and permeability still low</td>
</tr>
</tbody>
</table>

Sustained release formulations are a popular way to increase the efficiency of pharmacotherapy. This technology is easy to optimize, improves patient compliance and last, has a reasonable cost [28, 39]. Hydrophilic matrix systems assure controlled release, and have the advantages like the possibility to use conventional processes and equipment, and a wide range of active ingredients can be formulated. The polymers can swell in aqueous solution and form gel layer on the surface, leading to the extended release of the pharmacon [9, 36, 37]. Studies shown that formulation of silymarin in hydrophilic matrix
systems could be a promising way to improve bioavailability of the herbal drug [28, 52]. The results of novel *Silybum marianum* investigations were summarised in the Table I, representing the new effective formulations from this plant extract. It can be concluded that there is a shortage of reliable oral formulations with a proper bioavailability for silymarin therapy. It leads to the lack of effective hepatoprotective therapy and the expected effects in the treatment of cancer, or at least unexploited possibilities in a very important field of modern medicine.

The aim of our study was to produce a hydrophilic matrix tablet containing cyclodextrin encapsulated silymarin, a system which combines the advantages of increased solubility and the sustained release. Different silymarin-β-cyclodextrin complexes were formulated and carbopol based matrix tablets were prepared. 20 combinations were prepared for the testing of physical parameters, and in vitro dissolution and cytocompatibility tests were carried out to qualify their reliability. In the end, we could make a suggestion to the most proper product, according to our results.

**Materials and Methods**

**Materials**

*Silymarin*. Silymarin powder from *Silybum marianum* seeds was prepared according to Kahol et al. [14]. The main steps of the method are cooling and powdering the milk thistle seeds, defatting the seed powder, extracting it with acetonitrile, concentrating the powder, drying and filtering the material, and further purifying with acetonitrile, followed by filtering and drying. The silymarin powder did not contain any solvent residue. The same bioactive flavonolignans were determined as in the standards with the help of HPLC-MS method [26, 33].

**Matrix forming polymers.** Carbopol 71G, Noveon® AA-1 Polycarbophil USP, Carbopol 974 P NF, and Carbopol 971P were purchased from The Lubrizol Corporation (Wickliffe, Ohio, USA) [36].

**Complexing agents.** (2-Hydroxy)propyl-β-cyclodextrin (DS ~ 3 ± 1), Heptakis(2,6-di-O-methyl)-β-cyclodextrin, methylated β-cyclodextrin (DS ~ 12), and Random methyl-β-cyclodextrin (DS ~ 12) were obtained from CycloLab R&D Ltd. (Budapest, Hungary).

**Tablet’s excipients.** Mg-stearate, t alc, dibasic Ca-phosphate, KH₂PO₄, NaCl, HCl, and NaOH were obtained from Hungaropharma. Ludipress® was obtained from BASF (Ludwigshafen, Germany).

**Artificial gastric fluid.** Ingredients of artificial gastric fluid were 2.0 g NaCl and 80.0 mL of 1 M hydrochloric acid per litter, in accordance with the European Pharmacopoeia 9th Edition.

**Artificial intestinal fluid.** Ingredients of artificial intestinal fluid were 6.8 g KH₂PO₄ per litter and 0.1 M NaOH solution was used for adjusting pH to 6.8, in accordance with the European Pharmacopoeia 9th Edition.

**Cell culture.** Caco-2 cells were used for cytotoxicity studies. The cell line was obtained from European Collection of Cell Cultures (ECACC, Public Health England, Salisbury, UK).

**Cell culture medium.** 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), Dulbecco’s Modified Eagle’s Medium (DMEM), phosphate buffered saline (PBS), Trypsin–EDTA, Heat-inactivated foetal bovine serum (FBS), L-glutamine, non-essential amino acids solution, and penicillin–streptomycin were purchased from Sigma–Aldrich (St. Louis, Missouri, USA).

**Methods**

**Tablet Compressing.** Each product contained 70 mg silymarin as active ingredient, which is the single dose for adults. Silymarin-β-cyclodextrin complexes were made by physical mixture method: the drug and the different β-CD derivatives were weighted accurately in the required molar quantities (1:1), and mixed together in a mortar. 150 mg of carbopols were used in each tablet. As excipients of tablet pressing, 15 mg of Mg-stearate, 5 mg of t alc, 10 mg of dibasic Ca-phosphate, and the amount of Ludipress required for the total weight of 500 mg per tablet. The excipients ensured the glidant, lubricant, anti-adhesive and binding effects. Tablet ingredients were homogenized in mortar after being measured. For compressing, manual bench-top tablet press (Debrecen, Hungary) was used. Compressing force was 50 N. Four different matrix tablets were produced with four carbopol types, and 16 different tablet combinations were prepared, the compositions are presented in Table II and III.

**Table II**

Composition of carbopol-based matrix tablets

<table>
<thead>
<tr>
<th></th>
<th>1.</th>
<th>2.</th>
<th>3.</th>
<th>4.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Silymarin</td>
<td>70 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mg-stearate</td>
<td>15 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Talc</td>
<td>5 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ca-phosphate dibasic</td>
<td>10 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ludipress</td>
<td>250 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carbopol 71G</td>
<td>150 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Noveon AA-1 Polycarbophil USP</td>
<td>150 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>971 PNF</td>
<td></td>
<td>150 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>974 PNF</td>
<td></td>
<td></td>
<td>150 mg</td>
<td></td>
</tr>
</tbody>
</table>
Pharmaceutical Tests

Weight uniformity. For the test of tablet weight uniformity, 20 tablets were measured and the average weights were calculated. Then we investigated the deviation of the tablet weights from the average.

Friability. Tablet friability was measured using an Erweka TA40 friability tester (Heusenstamm, Germany). After carefully dedusted, the sample of 20 tablets was accurately weighed, then it was put in the drum of the tester. After 100 rotations of the drum, the loose dust was removed from the surface of the tablets and the tablets were weighed again.

Hardness. Tablet hardness was measured using an Erweka TBH30M tablet hardness tester (Heusenstamm, Germany). We investigated the breaking force of the sample of 10 tablets and averaged the results. All the methods and equipment used for pharmaceutical tests are in accordance with the European Pharmacopoeia 9th Edition.

Dissolution test

Dissolution studies were conducted using Erweka DT 800 Dissolution Tester (paddle method) (Heusenstamm, Germany). Dissolution medium was artificial intestinal fluid containing 6.8 g KH₂PO₄ per liter. 0.1 M NaOH solution was used for adjusting pH to 6.8. Temperature of the medium was 37 ± 0.5°C and it was constantly stirred through the tests, the paddle rotation speed was 100 rpm. Four replicates of each product were used, each tablet was put in 900 mL of medium. During the 13 hours of the tests, 16 samples were withdrawn, 4 mL each, with replacement of the medium.

For studies of dissolution in artificial gastric fluid, medium contained 2.0 g NaCl and 80.0 mL of 1 M hydrochloric acid per liter.

For the studies of dissolution in changing medium, we used the basket method of the dissolution tester. In the first hour, the tablets were in artificial gastric fluid as medium, and then we changed the medium to artificial intestinal fluid, and continued the test of the tablets for six hours more.

Silymarin concentration of the samples were measured by spectrophotometric method at 287 nm (Shimadzu UV-1601 UV-VIS Spectrophotometer, Kyoto, Japan). For reference, 70 mg silymarin or silymarin-cyclo-dextrin complex containing 70 mg active pharmaceutical ingredient (API) was solved in water then filtered. Sample absorbances are expressed as the percentage of the reference.

Cells culturing

Caco-2 cells were used for cytotoxicity studies. The cell line was obtained from European Collection of Cell Cultures. Cells were grown in plastic cell culture flasks in Dulbecco’s Modified Eagle’s Medium, supplemented with 3.7 g/L NaHCO₃, 10% (v/v) heat-inactivated foetal bovine serum (FBS), 1% (v/v) non-essential amino acids solution, 1% (v/v) L-glutamine, 100 IU/mL penicillin, and 100 IU/mL streptomycin in an atmosphere of 5% CO₂ at 37°C. Used medium was replaced with fresh in every 72 hours. The cells were maintained by regular passaging, and passage numbers were between 20 and 40 in case of cells used for cytotoxicity experiments [42].

MTT cell viability test

For the cytotoxicity tests, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was used to determine the viability of Caco-2 cells. On flat bottom 96-well tissue culture plates, seeded at a density of 10,000 cells in each plate, cells were allowed to grow for 7 days in CO₂ incubator, at 37°C.

For testing carbopol cytotoxicity as matrix-forming component of different tablets alone, the medium was removed from the cells and carbopol solutions were added, followed by an incubation period of 30 minutes.

For testing the tablet biocompatibility, samples from the dissolution test were used to treat the cells. After it, samples were removed, and the cells were incubated for a further 3 hours in a medium contained MTT at a concentration of 0.5 mg/mL. The purple formazan crystals produced by the cells were dissolved in isopropanol solution (isopropanol:1.0 N hydrochloric acid 25:1). The absorbance was measured at 570 nm against a 690 nm reference with FLUOstar OPTIMA Microplate Reader. The viability of cells was expressed as the percentage of the untreated control [30].
Statistical analysis
Data were analysed using GraphPad Prism (version 6.1, GraphPad Software Inc., San Diego, California, USA). To compare the groups in dissolution tests, two-way ANOVA (Tukey’s test of additivity) was performed. First time of significant difference between two dissolution curves and the first time of significant differences between all the compositions were examined.

Results and Discussion
Pharmaceutical tests
Weight uniformity. Weight uniformity test resulted in maximum deviation less than the allowed 5%. The highest deviation from the average weight was measured in the case of those tablets which contained Carbopol 71G, especially the composition without cyclodextrin. Tablets containing Carbopol 974 PNF showed the lowest deviation from the average, even as low as 0.5%. Results are depicted in Table IV and Table V. The table shows the average weight of 20 tablets of each composition, and the maximum deviation.

Table IV
Weight uniformity of matrix tablets

<table>
<thead>
<tr>
<th></th>
<th>71G</th>
<th>Noveon</th>
<th>971 PNF</th>
<th>974 PNF</th>
</tr>
</thead>
<tbody>
<tr>
<td>average</td>
<td>504.8</td>
<td>497.9</td>
<td>496.1</td>
<td>494.8</td>
</tr>
<tr>
<td>deviation</td>
<td>± 17.5</td>
<td>± 4.9</td>
<td>± 8.6</td>
<td>± 2.5</td>
</tr>
</tbody>
</table>

Table V
Weight uniformity of matrix tablets containing cyclodextrin-complexed silymarin

<table>
<thead>
<tr>
<th></th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
</tr>
</thead>
<tbody>
<tr>
<td>average</td>
<td>497.2</td>
<td>494.7</td>
<td>496.1</td>
<td>494.7</td>
<td>499.8</td>
<td>495.7</td>
<td>503.7</td>
<td>497.8</td>
</tr>
<tr>
<td>deviation</td>
<td>± 6.4</td>
<td>± 5.6</td>
<td>± 4.5</td>
<td>± 2.4</td>
<td>± 8.9</td>
<td>± 9.4</td>
<td>± 2.5</td>
<td>± 4.9</td>
</tr>
<tr>
<td>average</td>
<td>499.3</td>
<td>504.8</td>
<td>494.5</td>
<td>497.3</td>
<td>498.1</td>
<td>497.4</td>
<td>500.7</td>
<td>497.9</td>
</tr>
<tr>
<td>deviation</td>
<td>± 7.8</td>
<td>± 8.2</td>
<td>± 5.9</td>
<td>± 6.4</td>
<td>± 7.3</td>
<td>± 5.8</td>
<td>± 7.4</td>
<td>± 9.3</td>
</tr>
</tbody>
</table>

Friability. In case of every tablet, friability loss was less than the allowed 1%. The highest friability loss occurred in the case of tablets containing Carbopol 71G, while the compositions containing the other three carbopols did not show significant difference in friability. Results are presented in Table VI and Table VII. Loss is the difference between the weight of 20 tablets before and after the 100 rotations in the friability testing drum, and is under 1% in every case.

Table VI
Friability of matrix tablets

<table>
<thead>
<tr>
<th></th>
<th>71G</th>
<th>Noveon</th>
<th>971 PNF</th>
<th>974 PNF</th>
</tr>
</thead>
<tbody>
<tr>
<td>loss</td>
<td>49.2</td>
<td>26.2</td>
<td>27.2</td>
<td>24.0</td>
</tr>
<tr>
<td>%</td>
<td>0.54</td>
<td>0.29</td>
<td>0.27</td>
<td>0.26</td>
</tr>
</tbody>
</table>

Table VII
Friability of matrix tablets containing cyclodextrin-complexed silymarin

<table>
<thead>
<tr>
<th></th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
</tr>
</thead>
<tbody>
<tr>
<td>loss</td>
<td>53.9</td>
<td>28.7</td>
<td>33.7</td>
<td>27.7</td>
<td>45.9</td>
<td>30.7</td>
<td>30.2</td>
<td>34.8</td>
</tr>
<tr>
<td>%</td>
<td>0.5</td>
<td>0.32</td>
<td>0.34</td>
<td>0.25</td>
<td>0.46</td>
<td>0.31</td>
<td>0.3</td>
<td>0.35</td>
</tr>
</tbody>
</table>

Hardness. As for the hardness test, the tablets proven to be well compressed. Compositions with Carbopol 71G proved to be the softest tablets, while compositions containing the other three types of carbopol did not show significant difference in hardness. Results are depicted in Table VIII and Table IX. The results are expressed as the average force in Newton which was enough to break 10 tablets of each composition.

Table VIII
Hardness of matrix tablets

<table>
<thead>
<tr>
<th></th>
<th>71G</th>
<th>Noveon</th>
<th>971 PNF</th>
<th>974 PNF</th>
</tr>
</thead>
<tbody>
<tr>
<td>average</td>
<td>327</td>
<td>493</td>
<td>493</td>
<td>492</td>
</tr>
</tbody>
</table>

Considering the results of the pharmaceutical test, we can state that even though the use of a manual bench press as the equipment for tablet production, the physical parameters proven to be proper. All
our samples fulfilled the same requirements as the commercial pharmaceutical products.

**Table IX**

<table>
<thead>
<tr>
<th>Hardness</th>
<th>1.</th>
<th>2.</th>
<th>3.</th>
<th>4.</th>
<th>5.</th>
<th>6.</th>
<th>7.</th>
<th>8.</th>
<th>Average</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>337</td>
<td>488</td>
<td>489</td>
<td>487</td>
<td>342</td>
<td>473</td>
<td>508</td>
<td>476</td>
<td>N</td>
</tr>
<tr>
<td></td>
<td>316</td>
<td>484</td>
<td>510</td>
<td>480</td>
<td>310</td>
<td>495</td>
<td>487</td>
<td>486</td>
<td>N</td>
</tr>
</tbody>
</table>

**Carbopol cytotoxicity**

Cytotoxicity of all the four carbopols were tested by MTT assay on Caco-2 cell line. Correlation was not found between cell viability and carbopol concentration. The concentration of the carbopol solutions were steadily increasing, the examined maximum concentration was 150 mg of carbopol (the quantity one tablet contains) in 900 mL water. The highest cell viability occurred in the case of Noveon. Figure 1 shows the result of MTT assay in the function of carbopol concentration against the percentage of surviving cells. 100% was the cell survival in the case when cells were untreated. Each data point represents the mean ± S.D., n = 5.

**Dissolution of silymarin from matrix tablets**

In the first series of dissolution tests, we examined the silymarin release from the carbopol-based hydrophilic matrix tablets. Results are shown in Figure 2. Each data point represents the mean ± S.D. of four experiments. As we can see, all the four carbopols assured the sustained release of the silymarin. There was difference between the amount of released pharmacon, Carbopol 971P and Noveon being the two polymers with high amount of released silymarin after 780 minutes of dissolution. According to Tukey’s test, the first significant difference occurred at 60 minutes between Carbopol 971P and 71G. At 780 minutes, all the 4 dissolution curves differed significantly from each other. Carbopols were proven suitable as the base of a sustained release hydrophilic matrix tablet.

**Figure 1.**

Polymers MTT-cytotoxicity test

**Figure 2.**

Dissolution curves of carbopol based hydrophilic matrix tablets
Dissolution of complexed silymarin from matrix

The second series of dissolution tests aimed to examine the pharmacon release in case of hydrophilic matrix technology combined with cyclodextrin complexation. We carried out the dissolution test for all the 16 combinations of the four types of β-cyclodextrin derivatives and the four carbopols. We compared the dissolution curves. Based on the test results, two of the carbopols (Noveon and Carbopol 974 PNF) were selected which shown the highest amount of released silymarin during the 780 minutes time period. Based on Tukey’s test, the first significant difference occurred at 120 minutes between Carbopol 974 and 71G, and between 974 and 971. Noveon and Carbopol 974 dissolution curves did not differ significantly until the end of the examination, according to the test.

Dissolution curves of carbopol based hydrophilic matrix tablets containing silymarin complexed with randomly methylated β-cyclodextrin can be seen in Figure 3. Each data point represents the mean ± S.D. of four experiments. The amount of released active ingredient was the highest in the case of Carbopol 974 PNF and Noveon. According to Tukey’s test, the first significant difference occurred at 120 minutes between Carbopol 974 and 71G, and between 974 and 971. Noveon and Carbopol 974 dissolution curves did not differ significantly until the end of the examination, according to the test.

Figure 3.
Dissolution curves of carbopol based hydrophilic matrix tablets containing silymarin complexed with randomly methylated β-cyclodextrin

Dissolution curves of carbopol based hydrophilic matrix tablets containing silymarin complexed with Heptakis (2,6-di-O-methyl)-β-cyclodextrin can be seen in Figure 4. Each data point represents the mean ± S.D. of four experiments. The amount of released active ingredient was the highest in the case of Carbopol 974 PNF and Noveon. According to Tukey’s test, the first significant difference occurred at 60 minutes between Carbopol 971 and Noveon. At 480 minutes, all the 4 dissolution curves differed significantly from each other.

Figure 4.
Dissolution curves of carbopol based hydrophilic matrix tablets containing silymarin complexed with Heptakis (2,6-di-O-methyl)-β-cyclodextrin
Dissolution curves of carbopol based hydrophilic matrix tablets containing silymarin complexed with methylated β-cyclodextrin DS-12 can be seen in Figure 5. Each data point represents the mean ± S.D. of four experiments. The amount of released active ingredient was the highest in the case of Carbopol 974 PNF and Noveon. According to Tukey’s test, the first significant difference occurred at 180 minutes between Carbopol 71G and Noveon, 974. Noveon and Carbopol 974 dissolution curves did not differ significantly until the end of the examination, nor 71G and 971, according to the test.

Dissolution curves of carbopol based hydrophilic matrix tablets containing silymarin complexed with 2-hydroxipropyl β-cyclodextrin can be seen in Figure 6. Each data point represents the mean ± S.D. of four experiments. The amount of released active ingredient was the highest in the case of Carbopol 974 PNF and Noveon. According to Tukey’s test, the first significant difference occurred at 60 minutes between Carbopol 974 and 71G, 971. At 240 minutes, all the 4 dissolution curves differed significantly from each other.

Dissolution in acidic medium
In the third set of dissolution tests, we examined the silymarin release of carbopol based hydrophilic matrix tablets in artificial gastric juice. The pharmacon was complexed with hydroxy-propyl beta cyclodextrin. In this case, all carbopols shown the sustained drug release, but the dissolution was much slower in the process than in the previous tests with artificial intestinal fluid. In the end of the 780 minutes tests, the amount of dissolved silymarin was between 14% and 37%. The dissolution curves are shown on Figure 7. Each data point represents the mean ± S.D.
of four experiments. According to Tukey’s test, the first significant difference occurred at 5 minutes between Noveon and Carbopol 974. Noveon and Carbopol 71G dissolution curves did not differ significantly until the end of the examination, according to the test.

![Figure 7](image)

**Figure 7.**
Dissolution curves of carbopol based hydrophilic matrix tablets containing silymarin complexed with 2-hydroxypropyl β-cyclodextrin in artificial gastric juice, pH = 1.2

*Dissolution in altered medium*
In the fourth set of dissolution tests, the medium was artificial gastric juice in the first hour, and then we changed it to artificial intestinal fluid for six hours more. Our aim was to examine the behaviour of the carbopol matrix in an environment with pH conditions similar to the human GI system. We carried out the dissolution tests for all the 16 carbopol-cyclodextrin combinations. In these cases, the amount of released silymarin was less than the previous tests, partly because of shorter time, partly because of the acidic medium in the first hour, which affected the dissolution.

Comparing the dissolution curves, we could find those combinations of carbopols and cyclodextrins which are supposed to have the best pharmacon release.

Dissolution curves of carbopol based hydrophilic matrix tablets containing silymarin complexed with methylated β-cyclodextrin DS-12 in altered medium can be seen in Figure 8. Each data point represents the mean ± S.D. of four experiments. The amount of released active ingredient was the highest in the case of Carbopol 974 PNF and Noveon. The two other carbopols released only a low quantity of silymarin. According to Tukey’s test, Carbopol 974 and Noveon differed significantly from 971 and 71G from the beginning of the examination, but not from each other until the end of examination.

![Figure 8](image)

**Figure 8.**
Dissolution curves of carbopol based hydrophilic matrix tablets containing silymarin complexed with methylated β-cyclodextrin DS-12 in altered medium
Dissolution curves of carbopol based hydrophilic matrix tablets containing silymarin complexed with Heptakis (2,6-di-O-methyl)-β-cyclodextrin in altered medium can be seen in Figure 9. Each data point represents the mean ± S.D. of four experiments. The amount of released active ingredient was the highest in the case of Carbopol 974 PNF and Noveon, but all of the four carbopols released only a low quantity of silymarin. According to Tukey’s test, the first significant difference occurred at 15 minutes between Carbopol 71G and Noveon. Carbopol 971 and Carbopol 71G dissolution curves did not differ significantly until the end of the examination, according to the test.

Dissolution curves of carbopol based hydrophilic matrix tablets containing silymarin complexed with randomly methylated β-cyclodextrin in altered medium are presented in Figure 10. Each data point represents the mean ± S.D. of four experiments. The amount of released active ingredient was the highest in the case of Carbopol 974 PNF and Noveon, but all of the four carbopols released only a low quantity of silymarin. According to Tukey’s test, the first significant difference occurred at 15 minutes between Carbopol 71G and 974. Carbopol 971 and Carbopol 71G dissolution curves did not differ significantly until the end of the examination, according to the test.

Dissolution curves of carbopol based hydrophilic matrix tablets containing silymarin complexed with 2-hydroxipropil β-cyclodextrin in altered medium are depicted in Figure 11. Each data point represents the mean ± S.D. of four experiments. The amount of released active ingredient was the highest in the case of Carbopol 974 PNF and Noveon, but all of the four carbopols released only a low quantity of silymarin.
silymarin. According to Tukey’s test, the first significant difference occurred at 30 minutes between Carbopol 71G and 974. Carbopol 971 and Carbopol 71G dissolution curves did not differ significantly until the end of the examination, according to the test.

**Figure 11.**
Dissolution curves of carbopol based hydrophilic matrix tablets containing silymarin complexed with 2-hydroxipropil β-cyclodextrin in altered medium

**Dissolution of different silymarin preparations**
Examining the results of the dissolution tests, two combinations of carbopols and cyclodextrins assuring the most favourable properties for sustained release and increased bioavailability of silymarin can be selected. We carried out the dissolution test in altered medium for a commercial product, which was a conventional capsule with 70 mg silymarin as active ingredient. The dissolution curves of the commercial capsule and the Noveon and Carbopol 974 PNF based matrix tablets containing silymarin complexed with methylated β-cyclodextrin in both cases are shown in Figure 12. While the silymarin release of the conventional capsule peaked after the first hour, the matrix tablets implemented sustained release for six hours. The complexation with cyclodextrin increased the solubility of the active ingredient, resulting in a higher dissolved quantity. Each data point represents the mean ± S.D. of four experiments. According to Tukey’s test, the dissolution curve of the commercial product differs significantly from the matrix tablets since the 15th minutes. The dissolution curves of the two matrix tablets did not differ significantly from each other until the end of the examination.

**Figure 12.**
Dissolution of the commercial capsule and the Noveon and Carbopol 974 PNF based matrix tablets containing silymarin complexed with methylated β-cyclodextrin in altered medium

**Cytotoxicity test of Noveon based matrix tablets**
In the end, we repeated the dissolution test for the tablet containing the most suitable carbopol-cyclodextrin combination, Noveon and methylated β-cyclodextrin. Although there were no significant differences between the dissolution from the Noveon and Carbopol
974 PNF, the former showed slightly higher amount of dissolved API. We used the samples taken during the test for an MTT assay. Results can be seen in Figure 13. Correlation was not found between the concentration of tablet components and the percentage of surviving cells. Cell viability was higher than 70% in case of each sample, and at certain points it was almost 100%. The assay proved the tablet cytocompatible. Each data point represents the mean ± S.D. of five experiments.

![Figure 13](image)

**Figure 13.**
MTT-cytotoxicity test results of Noveon based matrix tablets containing silymarin complexed with methylated β-cyclodextrin

Silymarin has a wide range of effects, hepatoprotective properties principally [38]. Being a natural pharmacon with negligible side effect, higher patient compliance can be expected for the therapy [13]. Although there are studies about pharmacons showing better hepatoprotectivity [15], silymarin is still one of the most potent agents on this field of medicine, and is definitely worth the attention of scientists. That was the reason that our aim was to prepare effective modified (sustained) release matrix tablets containing *Silybum marianum* herb extract for oral administration.

The main disadvantage of silymarin is its very low bioavailability, there are reviews reporting its limitations resulted in the lack of clinical efficacy [6]. There are several possibilities to improve bioavailability via solubility, permeability, metabolism, and excretion [11, 12].

In our study, different β-cyclodextrins were selected to increase the solubility profile of silymarin. Cyclodextrins are efficient excipients used in pharmaceutical industry for increasing solubility, bioavailability, stability and prevention of irritation and incompatibility in oral, rectal, nasal and transdermal drug delivery systems [46]. We used physical mixture method for complexation according to Ghosh *et al.* [10]. Although, the phase solubility data and the stability constant of 722 K$^\circ$ confirms this method, the number of different silymarin components leads to further concerns regarding to the actual compounds being complexed. However, investigations were carried out to examine the complexation of multicomponent herbal drugs. Despite the lack of stability constant or even the accurate inclusion complexes of compounds, Yeh *et al.* proven the solubility enhancement and increased efficiency of San Huang Shel Shin Tang after complexation not only in *vitro* models, but in *vivo* experiments too [51]. We experienced that the solubility of *Silybum marianum*-β-cyclodextrin complex was 115% higher compared to the filtered solution of silymarin in the same quantity.

We chose hydrophilic matrix technology to assure sustained release. It is a relatively cheap method, and the production does not require special equipment, devices for producing conventional tablets are suitable. Several studies investigated the effect of β-cyclodextrin complexation combined with hydrophilic matrix technology, and proven enhanced bioavailability in the case of poorly soluble APIs like carbamazepine [22], nicardipine [1], diclofenac [17] and theophylline [38]. Carbopols are well-known materials used for topical gels, and their property of possessing carboxyl acid function makes their dissolution affected by the pH of the medium [37]. Our results showed that dissolution is decreased in lower pH from carbopol-matrix, which is favourable in the oral therapy leading to decreased quantity of active ingredient loss in the stomach. In addition, the result of cytotoxicity assays supported the cyto-compatibility of carbopols. The standard pharmaceutical tests showed that the physical parameters of our tablets are in accordance with the requirements of the European Pharmacopoeia 9th.

Considering the results of the dissolution tests, two compositions showing the best properties for a possible therapeutic use can be selected: the combinations of Noveon and Carbopol 974 PNF with methylated β-cyclodextrin.
There have been concerns for the toxicity of cyclodextrins for decades [3, 9, 27]. According to Kiss et al. [20, 21], there are differences in the cytotoxicity of different beta cyclodextrin derivatives in a concentration dependent manner. The results of our MTT-test may support of these investigations because the most suitable compositions showed highest cell viability proved the safety profile of our products.

Conclusions

Silymarin is worth the interest of scientific research considering not only its pharmacology and wide range of therapeutical effects, but the trend of high patient compliance toward natural and herbal medicines too.

The modern pharmaceutical technology offers several ways to overstep its limitations. Our research shows that combining β-cyclodextrins and carbopols, we can establish a sustained release system with enhanced bioavailability which can assure better therapeutic effects than the conventional commercial products in use and are relatively cheap and easy to produce.

References